Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Xortx Therapeutics Inc (XRTX.VN)

Xortx Therapeutics Inc (XRTX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Xortx Therapeutics Inc 3710 - 33rd Street NW Calgary AB T2L 2M1 CAN

https://www.xortx.com P: 403-607-2621 F: 403-260-3501

Description:

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Key Statistics

Overview:

Market Capitalization, $K 6,286
Shares Outstanding, K 3,224
Annual Sales, $ 0 K
Annual Net Income, $ -2,158 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ 170 K
60-Month Beta 0.52

Growth:

1-Year Return -40.00%
3-Year Return -93.53%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.06 on 08/15/24
Next Earnings Date N/A
Earnings Per Share ttm -0.37
EPS Growth vs. Prev Year -87.56%
Dividend Payout Ratio 0.00%
Most Recent Split 1-9 on 11/14/23

XRTX.VN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -29.36%
Return-on-Assets % -23.54%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 1.66
Book Value/Share 1.17
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar